Neoadjuvant PD-1 Blockade in Surgically Resectable Desmoplastic Melanoma: Cohort A of the Phase 2 SWOG S1512 Trial
- 4 June 2026
- journal article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (8) , 6927-6929
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trialNature Cancer, 2026
- Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trialNature Medicine, 2025
- Survival among patients treated with total mesorectal excision or selective watch-and-wait after total neoadjuvant therapy: a pooled analysis of the CAO/ARO/AIO-12 and OPRA randomized phase II trialsAnnals of Oncology, 2025
- Desmoplastic melanoma in Sweden in 2009–2022: A population‐based registry study demonstrating distinctive tumour characteristics, incidence and survival trendsJournal of the European Academy of Dermatology and Venereology, 2025
- Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III MelanomaNew England Journal of Medicine, 2024
- Desmoplastic melanomaClinics in Dermatology, 2024
- Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced MelanomaNew England Journal of Medicine, 2023
- Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia NomogramJournal of Clinical Oncology, 2020
- Fatal Toxic Effects Associated With Immune Checkpoint InhibitorsJAMA Oncology, 2018
- Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathwayNature Genetics, 2015